Company:  SYNTA PHARMACEUTICALS COR ... (SNTA)
Form Type:  10-Q
Filing Date:  4/30/2013 
CIK:  0001157601 
Address:  45 HARTWELL AVE 
City, State, Zip:  LEXINGTON, Massachusetts 02421 
Telephone:  781-274-8200 
Fiscal Year:  12/31 
Last Trade
Last Trade: 
$4.15  
Change: 
-0.04 (-0.96%)  
Trade Time: 
04:00 PM EST  
Market Cap: 
$380.28M
Description of Business
Synta Pharmaceuticals Corp. is a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to extend and enhance the lives of patients with cancer and other severe medical conditions. Our lead drug candidate, ganetespib, is a next generation Hsp90 inhibitor in Phase 3 development for non-small cell lung cancer (NSCLC) and in a broad development program including clinical trials for breast cancer, ovarian cancer and acute myeloid leukemia (AML). In addition, we are developing a unique, proprietary platform for enhanced delivery of anti-cancer drugs directly to tumor cells, known as Hsp90-inhibitor drug conjugates (HDCs). All of our drug candidates were invented by Synta scientists and are fully owned by Synta. In 2013, we made significant progress in expanding the breadth of the ganetespib development program and developing our HDC platform.
Register for EDGAR Pro and access this filing in:     
  FORM 10-Q
    PART I - FINANCIAL INFORMATION
      Item 1. Financial Statements.
        BALANCE SHEET
        INCOME STATEMENT
        CASH FLOW
        Notes to Condensed Consolidated Financial Statements
      Item 2. Management's Discussion and Analysis of Financial ...
      Item 3. Quantitative and Qualitative Disclosures About ...
      Item 4. Controls and Procedures.
    PART II - OTHER INFORMATION
      Item 1. Legal Proceedings.
      Item 1A. Risk Factors.
      Item 2. Unregistered Sales of Equity Securities and Use of ...
      Item 3. Defaults Upon Senior Securities.
      Item 4. Mine Safety Disclosures.
      Item 5. Other Information.
      Item 6. Exhibits.
    SIGNATURES
  EXHIBIT 10.2
  EXHIBIT 10.3
  EXHIBIT 31.1
    CERTIFICATIONS UNDER SECTION 302
  EXHIBIT 31.2
    CERTIFICATIONS UNDER SECTION 302
  EXHIBIT 32.1
    CERTIFICATIONS UNDER SECTION 906
BROKERAGE PARTNERS